According to the FDA, Fast Track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical
The companies have signed a letter of intent to enter into collaboration for the development of a novel coronavirus vaccine by using their technologies. GSK CEO Emma Walmsley
ASC09 has an unprecedented high genetic barrier to resistance and has completed Phase I and Phase IIa clinical trials, which have shown potent anti-viral activity. Previous clinical trials
As part of the deal, Alnylam will secure up to $2bn from Blackstone for the advancement of its RNAi medicines, which are believed to have the potential to
“We are excited to advance EC-18 as a potent drug candidate against COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus, to improve patient health,” said Ki Young Sohn,
The FDA approval was based on positive data from the National Cancer Institute (NCI) Cancer Therapy Evaluation Programme (CTEP)-sponsored phase II SPRINT Stratum 1 study organised by the
A cohort of 230 subjects with severe clinical symptoms will be randomized and administered a single dose of CD24Fc (480 mg IV infusion) or placebo and followed for
Braftovi, an oral small molecule kinase inhibitor, has been developed to target BRAF V600E. The approval was based on data from the BEACON CRC trial, which is claimed
This trial is expected to be performed in Italy, though additional studies are planned by CROMSOURCE for other countries in Europe as well as the United States. “The
The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammatory storm present in adults suffering from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.